Dichloroacetate / Cyt‑c Cancer Research Results

DCA, Dichloroacetate: Click to Expand ⟱
Features:
Dichloroacetate (DCA) is a metabolic modulator that targets the altered metabolic state of cancer cells by inhibiting PDKs. This action impacts several key pathways:

• Reversal of the Warburg effect
• Restoration of mitochondrial function and promotion of apoptosis
• suppresses glycolysis and promotes oxidative phosphorylation, thereby increasing mitochondrial ROS-mediated apoptosis in tumor cells • Increase in ROS production leading to oxidative stress
• Inhibition of cell cycle progression
• Modulation of HIF-1α signaling: DCA might decrease HIF-1α stabilization, thereby reducing the expression of genes that support glycolysis, angiogenesis, and survival under low-oxygen conditions.

-DCA has been primarily used in treating congenital lactic acidosis—a rare genetic disorder characterized by the buildup of lactic acid in the body.
-DCA is an anti-diabetic and lipid-lowering drug, as well as treating myocardial and cerebrovascular ischemia.

-Do not add DCA to hot or warm beverages. DCA is unstable at higher temperatures
-Caffeinated increases effectiveness
-Vitamin B1 reduces neuropathy (500mg-2500mg/day)
-Possibly 20 grams of citric acid 20 minutes before taking DCA
-Procaine, Diclofenac or Sulindac to increase SMCT1
-Omeprazole 80mg/day to increase DCA effectiveness
-Scorpion venom to increase DCA effectiveness
-Metformin 1000mg to 1500mg/day
-Propranolol (Ref.)
-Fenbendazole shows strong synergy when combined to DCA, So it may make very much sense to combine the two.
"Note: DCA is not tumor cell specific,> and therefore the same shift in glucose metabolism that occurs in cancer cells will also take place in immune cells, leading to induction of Tregs (Ref.). In order to avoid this possibility, while using DCA I would also use Treg inhibitors such as Cimetidine (Ref.) or low dose Cyclophosphamide (Ref.)."

Dose: 10mg/kg/day and increase slowly to about 25mg/kg/day:(1/2morn,1/2evening) take 5 days on, 2 off? OR 2wks on/ 1wk off: https://www.thedcasite.com/dca_dosage.html
Done by mixing it in water and drinking, suggested that DCA not be taken on an empty stomach.

****
DCA-induced apoptosis in cancer cells requires sodium-coupled monocarboxylates transporter SLC5A8 (SMCT1)
-Inhibitors of DNA methylation induce reactivation of SLC5A8
-Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.
-SMCT1 was found to be stimulated by some other NSAIDs (diclofenac, meclofenamate and sulindac), by activin A143 and by the probiotic Lactobacillus plantarum.

SMCT1 has been found to be inhibited by some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and indomethacin94), phytochemicals (resveratrol and quercetin) **** Hence these should be avoided with DCA. (also AVOID Bromide, iodide and sulfite )

****
GSTZ1 an/or chloride anion transport inhibitors also reduce resistance to DCA (if the tumor expresses GSTZ1 and contains a high chloride anions level, the GSTZ1 will be stable, maintaining the resistance to DCA).

-Dichloroacetate-dca-treatment-strategy GSTZ1 an/or chloride anion transport inhibitors. .
-Etacrynic acid is a Cl(-)-ATPase inhibitor
-Lansoprazole and Omeprazole inhibit chloride channels.
-Chlorotoxin found in scorpion venom (see my post on scorpion venom) can also inhibit chlorine channels

Sources:
https://northernhealthproducts.com/shop/
https://www.dcalab.com/

Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 Pyruvate dehydrogenase kinase (PDK) → PDH gatekeeper ↓ PDK activity → ↑ active PDH (dephosphorylated) Warburg reversal (pyruvate into TCA) DCA’s canonical mechanism: inhibits PDK, restoring PDH activity and oxidative metabolism in cancer (ref)
2 Glycolysis output (lactate / ECAR) ↓ lactate production / ↓ ECAR Reduced acidification; metabolic reprogramming DCA decreases PDH phosphorylation and lowers glycolytic output (lactate/ECAR) in cancer models (ref)
3 Mitochondrial membrane potential remodeling (ΔΨm) ↓ cancer-associated mitochondrial hyperpolarization (depolarization) Restores apoptosis susceptibility Glioblastoma work: DCA reverses cancer-specific mitochondrial remodeling (hyperpolarization → depolarization), enabling apoptosis (ref)
4 ROS generation (especially under hypoxia) ↑ ROS Oxidative stress trigger DCA increases ROS in hypoxic cancer cells (reported strongly under hypoxia), linking metabolic shift to cytotoxic stress (ref)
5 Voltage-gated K+ channel axis (Kv1.5) / NFAT signaling ↑ Kv1.5 expression/activity Pro-apoptotic electrophysiology shift Endometrial cancer study: DCA engages mitochondrial + NFAT–Kv1.5 mechanisms associated with apoptosis sensitization (ref)
6 Intrinsic apoptosis (mitochondrial pathway) ↑ apoptosis Programmed cell death DCA induces apoptosis in glioblastoma and endometrial cancer models as mitochondrial remodeling is reversed (ref)
7 PUMA-mediated apoptotic priming ↑ PUMA-dependent sensitization Lower apoptotic threshold Endometrial cancer paper explicitly reports a PUMA-mediated component in DCA apoptosis sensitization (ref)
8 Hypoxia resistance axis (HIF-1α / PDK1) ↓ hypoxia-associated resistance (HIF-1α/PDK1 axis engaged) Improved treatment responsiveness DCA attenuates hypoxia-associated resistance in gastric cancer context with reported linkage to HIF-1α and PDK1 (ref)
9 Radiosensitization (hypoxic tumor cells) ↑ radiosensitivity (esp. under hypoxia) Therapy potentiation DCA increases ROS under hypoxia and enhances radiotherapy response in TNBC models (ref)
10 In vivo / translational anti-tumor activity (glioblastoma) ↓ tumor growth / ↓ proliferation (model-dependent) Demonstrated anti-tumor effect Glioblastoma study includes translational evidence that DCA can reverse tumor metabolic remodeling with anti-tumor effects (ref)


Cyt‑c, cyt-c Release into Cytosol: Click to Expand ⟱
Source:
Type:
Cytochrome c
** The term "release of cytochrome c" ** an increase in level for the cytosol.
Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis.

The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis.
In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death.
Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation.
Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol.
The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death.

On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer.
On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells.
Overexpressed in Breast, Lung, Colon, and Prostrate.
Underexpressed in Ovarian, and Pancreatic.


Scientific Papers found: Click to Expand⟱
5196- DCA,    Dichloroacetate induces apoptosis in endometrial cancer cells
- in-vitro, Var, NA
selectivity↑, MMP↓, survivin↓, Ca+2↓, P53↑, PDK1↓, PDH↑, Glycolysis↓, OXPHOS↑, ROS↑, Cyt‑c↑, Apoptosis↑, Casp↑, tumCV↓, PUMA↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

OXPHOS↑, 2,   ROS↑, 3,  

Metal & Cofactor Biology

Ferritin↓, 1,  

Mitochondria & Bioenergetics

MMP↓, 1,  

Core Metabolism/Glycolysis

GlucoseCon↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   PDH↑, 1,   PDK1↓, 1,   PDKs↓, 1,  

Cell Death

Apoptosis↑, 2,   Casp↑, 1,   Casp3↑, 1,   Cyt‑c↑, 2,   PUMA↑, 1,   survivin↓, 1,  

Transcription & Epigenetics

tumCV↓, 1,  

Protein Folding & ER Stress

ER Stress↑, 1,  

Autophagy & Lysosomes

LC3s↓, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair

P53↑, 1,  

Proliferation, Differentiation & Cell State

CSCs↓, 1,   EMT↓, 1,   mTOR↓, 1,   TumCG↓, 2,  

Migration

Ca+2↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 1,   eff↑, 3,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers

Ferritin↓, 1,  

Functional Outcomes

OS↑, 1,   toxicity↝, 1,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Cyt‑c, cyt-c Release into Cytosol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:288  Target#:77  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page